How do leukaemia stem cells talk to the immune system in juvenile myelomonocytic leukaemia?
Find out how JMML cells are able to switch off the immune system, causing relapse.
Understanding why some childhood blood cancers are incurable
Using models to find out how high risk leukaemia cells grow and become resistant to treatment.
What factors affect the survival of children and young people with high-risk acute lymphoblastic leukaemia?
Finding out what makes ALL more high-risk, such as age of diagnosis or type of initial treatment.
Investigating clinical trial samples to predict how atypical teratoid rhabdoid tumours will respond to treatment
Looking at cancer samples to find markers that can predict how a child's cancer will respond to treatment.
Creating a new immunotherapy approach to fight aggressive medulloblastoma
Finding a way to use immunotherapy against a high-risk type of childhood brain tumour.
Confirming bloodstream markers of children’s kidney cancer
Identifying markers that can be used for a non-invasive test to diagnose and monitor Wilms tumour.
Blocking processes which keep leukaemia cells alive
Investigating the possibility of combining a medicine that blocks the process with a medicine that triggers a cell's defensive response to treat ALL.
Stopping drug resistant processes in T-cell acute lymphoblastic leukaemia
Developing a test to select patients who can be treated with a new medicine that prevents steroid resistance.
Blocking chemical reactions which keep ependymoma cells alive
Testing four medicines to see if they can shut down the metabolism of brain cancer cells grown in the lab